Palisade Bio, Inc.
PALI- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001357459
In the last 90 days, Palisade Bio, Inc. insiders filed 3 open-market purchases and 2 sales; 124 institutions reported holding it in 13F filings for Q2 2026, worth $362.4M in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Palisade Bio, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 9 | 11 | +2 |
| Shares | 8.44K | 134.6K | +126.1K (+1,494.6%) |
| Value | $29.8K | $228.7K | +$199.0K (+668.3%) |
New holders (5)
Institutions that held Palisade Bio, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Geode Capital Management, LLC | 42,247 | $71.8K | 0.00% |
| Vanguard Group Inc | 35,569 | $60.5K | 0.00% |
| Bank of America Corp | 30,000 | $51.0K | 0.00% |
| State Street Corp | 22,463 | $38.2K | 0.00% |
| Federation des caisses Desjardins du Quebec | 1,520 | $2.58K | 0.00% |
Sold out (3)
Institutions that held Palisade Bio, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Tower Research Capital LLC (TRC) | 2,479 | $9.00K |
| JPMorgan Chase & Co | 626 | $2.00K |
| Orion Capital Management LLC | 299 | $1.05K |